Literature DB >> 16942026

Structure-activity relationships of uridine 5'-diphosphate analogues at the human P2Y6 receptor.

Pedro Besada1, Dae Hong Shin, Stefano Costanzi, Hyojin Ko, Christophe Mathé, Julien Gagneron, Gilles Gosselin, Savitri Maddileti, T Kendall Harden, Kenneth A Jacobson.   

Abstract

The structure-activity relationships and molecular modeling of the uracil nucleotide activated P2Y6 receptor have been studied. Uridine 5'-diphosphate (UDP) analogues bearing substitutions of the ribose moiety, the uracil ring, and the diphosphate group were synthesized and assayed for activity at the human P2Y6 receptor. The uracil ring was modified at the 4 position, with the synthesis of 4-substituted-thiouridine 5'-diphosphate analogues, as well as at positions 2, 3, and 5. The effect of modifications at the level of the phosphate chain was studied by preparing a cyclic 3',5'-diphosphate analogue, a 3'-diphosphate analogue, and several dinucleotide diphosphates. 5-Iodo-UDP 32 (EC50 = 0.15 microM) was equipotent to UDP, while substitutions of the 2'-hydroxyl (amino, azido) greatly reduce potency. The 2- and 4-thio analogues, 20 and 21, respectively, were also relatively potent in comparison to UDP. However, most other modifications greatly reduced potency. Molecular modeling indicates that the beta-phosphate of 5'-UDP and analogues is essential for the establishment of electrostatic interactions with two of the three conserved cationic residues of the receptor. Among 4-thioether derivatives, a 4-ethylthio analogue 23 displayed an EC50 of 0.28 microM, indicative of favorable interactions predicted for a small 4-alkylthio moiety with the aromatic ring of Y33 in TM1. The activity of analogue 19 in which the ribose was substituted with a 2-oxabicyclohexane ring in a rigid (S)-conformation (P = 126 degrees , 1'-exo) was consistent with molecular modeling. These results provide a better understanding of molecular recognition at the P2Y6 receptor and will be helpful in designing selective and potent P2Y6 receptor ligands.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16942026      PMCID: PMC3405152          DOI: 10.1021/jm060485n

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  37 in total

Review 1.  P2Y receptors: biological advances and therapeutic opportunities.

Authors:  S R Shaver
Journal:  Curr Opin Drug Discov Devel       Date:  2001-09

2.  P2Y6 nucleotide receptors activate NF-kappaB and increase survival of osteoclasts.

Authors:  Jasminka Korcok; Lin N Raimundo; Xiaobing Du; Stephen M Sims; S Jeffrey Dixon
Journal:  J Biol Chem       Date:  2005-02-18       Impact factor: 5.157

3.  Purinergic P2Y6 receptors induce Ca2+ and CFTR dependent Cl- secretion in mouse trachea.

Authors:  Rainer Schreiber; Karl Kunzelmann
Journal:  Cell Physiol Biochem       Date:  2005

4.  Human neutrophil peptides induce interleukin-8 production through the P2Y6 signaling pathway.

Authors:  Aye Aye Khine; Lorenzo Del Sorbo; Rosanna Vaschetto; Stefanos Voglis; Elizabeth Tullis; Arthur S Slutsky; Gregory P Downey; Haibo Zhang
Journal:  Blood       Date:  2005-12-01       Impact factor: 22.113

5.  Human P2Y(6) receptor: molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference.

Authors:  Stefano Costanzi; Bhalchandra V Joshi; Savitri Maddileti; Liaman Mamedova; Maria J Gonzalez-Moa; Victor E Marquez; T Kendall Harden; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2005-12-29       Impact factor: 7.446

6.  Towards a revised nomenclature for P1 and P2 receptors.

Authors:  B B Fredholm; M P Abbracchio; G Burnstock; G R Dubyak; T K Harden; K A Jacobson; U Schwabe; M Williams
Journal:  Trends Pharmacol Sci       Date:  1997-03       Impact factor: 14.819

7.  Synthesis of oligoribonucleotides containing 4-thiouridine using the convertible nucleoside approach and the 1-(2-fluorophenyl)-4-methoxypiperidin-4-yl group.

Authors:  Anna Aviñó; Ramon Güimil García; Ramon Eritja
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2004       Impact factor: 1.381

8.  Identification of a novel human ADP receptor coupled to G(i).

Authors:  D Communi; N S Gonzalez; M Detheux; S Brézillon; V Lannoy; M Parmentier; J M Boeynaems
Journal:  J Biol Chem       Date:  2001-08-23       Impact factor: 5.157

9.  Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling.

Authors:  Stefano Costanzi; Liaman Mamedova; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2004-10-21       Impact factor: 7.446

10.  Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate.

Authors:  B Fischer; J L Boyer; C H Hoyle; A U Ziganshin; A L Brizzolara; G E Knight; J Zimmet; G Burnstock; T K Harden; K A Jacobson
Journal:  J Med Chem       Date:  1993-11-26       Impact factor: 7.446

View more
  32 in total

1.  Development of a comprehensive set of P2 receptor pharmacological research compounds.

Authors:  R A Felix; S Martin; S Pinion; D J Crawford
Journal:  Purinergic Signal       Date:  2011-11-04       Impact factor: 3.765

Review 2.  G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions.

Authors:  Kenneth A Jacobson; Ramachandran Balasubramanian; Francesca Deflorian; Zhan-Guo Gao
Journal:  Purinergic Signal       Date:  2012-02-29       Impact factor: 3.765

3.  Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications.

Authors:  Hiroshi Maruoka; Matthew O Barrett; Hyojin Ko; Dilip K Tosh; Artem Melman; Lauren E Burianek; Ramachandran Balasubramanian; Barkin Berk; Stefano Costanzi; T Kendall Harden; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2010-06-10       Impact factor: 7.446

Review 4.  Signalling and pharmacological properties of the P2Y receptor.

Authors:  T K Harden; J I Sesma; I P Fricks; E R Lazarowski
Journal:  Acta Physiol (Oxf)       Date:  2010-03-24       Impact factor: 6.311

5.  Structure-activity relationship of uridine 5'-diphosphoglucose analogues as agonists of the human P2Y14 receptor.

Authors:  Hyojin Ko; Ingrid Fricks; Andrei A Ivanov; T Kendall Harden; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2007-04-04       Impact factor: 7.446

6.  Attenuation of apoptosis in vitro and ischemia/reperfusion injury in vivo in mouse skeletal muscle by P2Y6 receptor activation.

Authors:  Liaman K Mamedova; Ruibo Wang; Pedro Besada; Bruce T Liang; Kenneth A Jacobson
Journal:  Pharmacol Res       Date:  2008-08-30       Impact factor: 7.658

7.  Purinergic receptors regulate myogenic tone in cerebral parenchymal arterioles.

Authors:  Joseph E Brayden; Yao Li; Matthew J Tavares
Journal:  J Cereb Blood Flow Metab       Date:  2012-11-21       Impact factor: 6.200

8.  Human P2Y(14) receptor agonists: truncation of the hexose moiety of uridine-5'-diphosphoglucose and its replacement with alkyl and aryl groups.

Authors:  Arijit Das; Hyojin Ko; Lauren E Burianek; Matthew O Barrett; T Kendall Harden; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2010-01-14       Impact factor: 7.446

9.  Radical-translocation intermediates and hurdling of pathway defects in "super-oxidized" (Mn(IV)/Fe(IV)) Chlamydia trachomatis ribonucleotide reductase.

Authors:  Laura M K Dassama; Wei Jiang; Paul T Varano; Maria-Eirini Pandelia; Denise A Conner; Jiajia Xie; J Martin Bollinger; Carsten Krebs
Journal:  J Am Chem Soc       Date:  2012-12-04       Impact factor: 15.419

10.  Development of selective agonists and antagonists of P2Y receptors.

Authors:  Kenneth A Jacobson; Andrei A Ivanov; Sonia de Castro; T Kendall Harden; Hyojin Ko
Journal:  Purinergic Signal       Date:  2008-07-04       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.